Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study

Background CheckMate 8KX was a phase I/II study investigating the pharmacokinetics and safety of subcutaneous (SC) nivolumab±recombinant human hyaluronidase PH20 (rHuPH20).Methods Patients with advanced solid tumors who were immune-checkpoint inhibitor-naïve were included. In parts A and B, patients...

Descrición completa

Detalles Bibliográficos

Principais autores:	Sara Lonardi, Christopher Jackson, R Donald Harvey, Armando Santoro, Iwona Lugowska, José Trigo, Anne O’Donnell, Richard North, Urvi Aras, Loes Maria Latten-Jansen, Linghui Li, Devanand Joseph, Bryan Bennett, Balmeet Gurm, Wee-Teck Ng, Aitana Calvo, Marcelo Garrido, Rastislav Bahleda, Matías Rodrigo Chacon, Heather E Vezina, Deepak Perumal
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMJ Publishing Group 2025-10-01
Series:	Journal for ImmunoTherapy of Cancer
Acceso en liña:	https://jitc.bmj.com/content/13/10/e011918.full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!